GlobeNewswire

Transcenta Therapeutics Presents New Data for its Novel LIV1-Targeting ADC TST013 Demonstrating Potent Anti-Tumor Activity in PDX Models of Prostate Cancer and ER Positive /HER2 Negative Breast Cancer
23/04/2026
PRINCETON, N.J. and SUZHOU, China, April 23, 2026 (GLOBE NEWSWIRE) -- Transcenta Therapeutics (HKEX: 06628), a global clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, [...]
Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder
23/04/2026
Dosing initiates clinical evaluation of NPX-5, a GMP-compliant, nature-derived psilocybin candidate across an expanded Australian site network NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq [...]
Verano Expands Retail Presence on Florida’s Emerald Coast with Opening of MÜV Miramar Beach, the Company’s 85th Florida Dispensary and 162nd Location Nationwide
23/04/2026
MÜV Miramar Beach, located on a busy stretch of scenic Highway 98 with an average daily traffic count of 48,000 vehicles 1 , is situated on Florida’s Emerald Coast near numerous popular beach and tourist areas Miramar [...]
AAVantgarde to Participate in ARVO 2026, with Presentations at Key Pre-events and New Clinical Data from the LUCE Phase 1/2 Study
23/04/2026
MILAN, April 23, 2026 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company pioneering next-generation gene therapies for inherited retinal diseases (IRDs) has today announced its [...]
Tonix Pharmaceuticals Presents Updates on Preclinical Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2026
23/04/2026
TNX-1700 (TFF2-albumin fusion protein) reversed aging-associated gastric inflammation and significantly attenuated tumor progression in aged gastric microenvironment in preclinical models TNX-1700 exhibited dose- [...]
Validic Launches Free Developer Tier with API-Driven, Agentic-Ready Self-Signup
23/04/2026
The connected health data company opens its health data platform to every developer and builder, with full support for agentic workflows — free to start, no contract, no sales call required DURHAM, N.C., April 23, 2026 [...]
BrewDog USA Doubles Down on Headliners and Ignites Next Wave of Innovation for Spring and Summer
23/04/2026
COLUMBUS, Ohio, April 23, 2026 (GLOBE NEWSWIRE) -- BrewDog USA by  Tilray Brands, Inc.  (NASDAQ: TLRY; TSX: TLRY), today unveiled its lineup of headliner products and bold innovation bets for spring and summer, [...]
Aveanna Announces First Quarter 2026 Earnings Release Date and Conference Call
23/04/2026
ATLANTA, April 23, 2026 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (“Aveanna”) (NASDAQ: AVAH) today announced that the company will release its first quarter results before the market open on Thursday, May 14 [...]
Greenwich LifeSciences Announces Acceptance of Abstract at ASCO 2026
23/04/2026
STAFFORD, Texas, April 23, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is [...]
Novo Nordisk’s oral semaglutide demonstrates potential to be the first oral GLP-1 RA therapy for children and adolescents with type 2 diabetes
23/04/2026
PIONEER TEENS is the first clinical trial of an oral GLP-1 RA therapy in children and adolescents aged 10–17 years with type 2 diabetes, addressing a significant unmet need. The trial demonstrated a statistically [...]
Orion Group Interim report January–March 2026
23/04/2026
ORION CORPORATION INTERIM REPORT 1–3/2026 23 APRIL 2026 at 12:00 EEST Orion Group Interim report January–March 2026 January–March 2026 Highlights Net sales totalled EUR 417.7 (January–March 2025: 354.6) million [...]
ENA Respiratory Appoints Melissa Faris to Board
23/04/2026
MELBOURNE, Australia, April 23, 2026 (GLOBE NEWSWIRE) -- ENA Respiratory , a clinical-stage pharmaceutical company developing antiviral host defence enhancers to minimize the impact of symptomatic viral respiratory [...]
Nectero Therapeutics Reports Two-Year Safety and Efficacy Data from First-in-Human Trial for Treatment of Small- to Medium-Sized Abdominal Aortic Aneurysms
23/04/2026
LONDON, April 23, 2026 (GLOBE NEWSWIRE) -- Nectero Therapeutics, a clinical-stage biotechnology company developing therapies for aneurysmal disease, released two-year outcomes data today from the company’s first-in- [...]
Epitopea Announces Approval of OVACT Clinical Trial Application for CryptiVax-1001 in Advanced High-Grade Serous Ovarian Cancer
23/04/2026
Appoints Leading Oncologist Professor Susana Banerjee of The Royal Marsden as Chief Investigator CAMBRIDGE, United Kingdom and MONTREAL, April 23, 2026 (GLOBE NEWSWIRE) -- Epitopea, a transatlantic biotech developing [...]
Epitopea annonce l'approbation de la demande d'essai clinique OVACT pour le CryptiVax-1001 dans le cancer de l'ovaire séreux de haut grade avancé
23/04/2026
Nomme la professeure Susana Banerjee, éminente oncologue du Royal Marsden, en tant que chercheuse principale CAMBRIDGE, Royaume-Uni et MONTRÉAL, 23 avr. 2026 (GLOBE NEWSWIRE) -- Epitopea, une société biotechnologique [...]
Zelluna ASA – Annual General Meeting held on April 23, 2026
23/04/2026
Oslo, April 23, 2026: Zelluna ASA held its annual general meeting on April 23, 2026. All matters on the agenda were approved. The minutes from the meeting are enclosed and are also available on the company’s website. [...]
Last patient, last visit completed in Phase I clinical trial of PulseSight Therapeutics’ PST-611 treatment for dry AMD/Geographic Atrophy (GA)
23/04/2026
-Results to be presented at ARVO 2026 Annual Meeting- PARIS, April 23, 2026 (GLOBE NEWSWIRE) -- PulseSight Therapeutics SAS, an ophthalmology clinical stage biotech company developing disruptive vectorized gene [...]
Pharming Group to report first quarter 2026 financial results and provide business update on May 7
23/04/2026
Leiden, the Netherlands, April 23, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms that it will report its preliminary (unaudited) financial results for the [...]
Orion Pharma initiates TEADCO Phase 1b/2 basket trial evaluating ODM-212 in combination with standard of care treatments in patients with select advanced solid tumours
23/04/2026
ORION CORPORATION PRESS RELEASE 23 APRIL 2026 at 09.00 EEST Orion Pharma initiates TEADCO Phase 1b/2 basket trial evaluating ODM-212 in combination with standard of care treatments in patients with select advanced solid [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum